Annie DELAUNOIS

Dr. Annie DELAUNOIS

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RBRichard J. Brennan
Richard J. Brennan
SJStephen Jenkinson
Stephen Jenkinson
ABAndrew Brown
Andrew Brown
ADAnnie DELAUNOIS
Annie DELAUNOIS
BDBérengère Dumotier
Bérengère Dumotier
JVJean-Pierre Valentin
Jean-Pierre Valentin

5 March 2025 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
THThierry Hanser
Thierry Hanser
EAErnst Ahlberg
Ernst Ahlberg
AAAlexander Amberg
Alexander Amberg
LALennart T. Anger
Lennart T. Anger
CBChris Barber
Chris Barber
TYTomoya Yukawa
Tomoya Yukawa

23 February 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
ADAnnie DELAUNOIS
Annie DELAUNOIS
MAMatthew Abernathy
Matthew Abernathy
WAWarren D. Anderson
Warren D. Anderson
KBKylie A. Beattie
Kylie A. Beattie
KCKhuram W. Chaudhary
Khuram W. Chaudhary
JVJean‐Pierre Valentin
Jean‐Pierre Valentin
We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine (OH‐CLQ)‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin (ERT) and azithromycin (AZI), drugs repurposed during the first wave of coronavirus disease 2019 (COVID‐19). Each drug or drug combination was tested in patch clamp assays on seven cardiac ion channels, in in silico models of human ventricular electrophysiology (Virtual Assay) using control (healthy) or high‐risk cell populations, and in human‐induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes. In each assay, concentration‐response curves encompassing and exceeding therapeutic free plasma levels were generated. Both CLQ and OH‐CLQ showed blocking activity against some potassium, sodium, and calcium currents. CLQ and OH‐CLQ inhibited IKr (half‐maximal inhibitory concentration [IC50]: 1 µM and 3–7 µM, respectively) and IK1 currents (IC50: 5 and 44 µM, respectively). When combining OH‐CLQ with AZI, no synergistic effects were observed. The two macrolides had no or very weak effects on the ion currents (IC50 > 300–1000 µM). Using Virtual Assay, both antimalarials affected several TdP indicators, CLQ being more potent than OH‐CLQ. Effects were more pronounced in the high‐risk cell population. In hiPSC‐derived cardiomyocytes, all drugs showed early after‐depolarizations, except AZI. Combining CLQ or OH‐CLQ with a macrolide did not aggravate their effects. In conclusion, our integrated nonclinical CiPA dataset confirmed that, at therapeutic plasma concentrations relevant for malaria or off‐label use in COVID‐19, CLQ and OH‐CLQ use is associated with a proarrhythmia risk, which is higher in populations carrying predisposing factors but not worsened with macrolide combination.

10 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MLMartin A. Lowe
Martin A. Lowe
ACAlvaro Cardenas
Alvaro Cardenas
JVJean-Pierre Valentin
Jean-Pierre Valentin
ZZZhaoning Zhu
Zhaoning Zhu
JAJan Abendroth
Jan Abendroth
THTeresa de Haro
Teresa de Haro
Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress and invasion of erythrocytes, development of functional liver merozoites (prophylactic activity), and blocking transmission to mosquitoes, making it a potential multistage drug target. We report the optimization of an aspartyl protease binding scaffold and the discovery of potent, orally active PMX inhibitors with in vivo antimalarial efficacy. Incorporation of safety evaluation early in the characterization of PMX inhibitors precluded compounds with a long human half-life (t1/2) to be developed. Optimization focused on improving the off-target safety profile led to the identification of UCB7362 that had an improved in vitro and in vivo safety profile but a shorter predicted human t1/2. UCB7362 is estimated to achieve 9 log 10 unit reduction in asexual blood-stage parasites with once-daily dosing of 50 mg for 7 days. This work demonstrates the potential to deliver PMX inhibitors with in vivo efficacy to treat malaria.

1 March 1993 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ADAnnie DELAUNOIS
Annie DELAUNOIS
PGP. Gustin
P. Gustin
MAM. Ansay
M. Ansay

1 July 2007 in Laboratory Animals
Verified
Journal Article
Open access
SKS Kaïdi
S Kaïdi
FBF Brutel
F Brutel
FDF Van Deun
F Van Deun
KKK Kramer
K Kramer
RRR Remie
R Remie
ODO Depelchin
O Depelchin
The goal of this study was to compare two surgical methods, the left carotid (LC) and the abdominal aorta (AA), for mouse instrumentation with telemetry devices, to determine the best method for measuring cardiovascular (CV) parameters by radiotelemetry in freely moving mice. Surgery success rate, postsurgical recovery rate, clinical parameters, CV data (baseline and response to nicotine) and circadian rhythm measurements were compared between these techniques. Brains of LC-implanted mice were evaluated for potential ischaemia by direct observation of the Circle of Willis anatomy and histopathology. For this purpose, a total of 31 CD-1 male mice were instrumented with PA C20 devices (10 with LC and 21 with AA). Mortality, morbidity, physical examination, body weight (BW), water and food consumption (W/FC), mean blood pressure (MBP) and heart rate (HR) were monitored daily during the recovery period (10 days). CV baseline data were recorded continuously during two periods of four days, and finally, both LC- and AA-implanted mice received an acute subcutaneous administration of 1 mg/kg nicotine; BP and HR were recorded during 5 h after nicotine administration. Results showed that, in LC-implanted mice, 80% survived surgery and recovered well. In contrast, only 57% of mice implanted with the AA technique survived surgery and some presented lethal complications. Both techniques had similar recovery times for BW and W/FC, comparable return to normal circadian rhythm (day 6 post-surgery) and similar CV baseline values. No significant differences were observed in CV response to nicotine between both groups of implanted CD-1 mice. No histopathological changes suggestive of ischaemia were noted in the brain of mice implanted in the LC. Six out of the eight LC-implanted mice remained in good health and had good pressure signal for at least 100 days post-surgery, while most of the AA-implanted mice lost the signal pressure within 14–49 days post-surgery. In conclusion, we believe that LC implantation in mice is superior to the AA technique and is more appropriate for long-term telemetry studies, especially for smaller (transgenic) animals.